Epigral Ltd
Epigral Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.
From Epigral Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries.
- Revenue contribution from derivatives and specialty business is targeted to increase from 50% in Q1 FY26 to 70% by FY28.
- The recently commissioned Chlorotoluene value chain is expected to generate sizable revenue by the end of FY26, with commercial order clarity by Q4 FY26.
- Expansion projects including doubling capacities of CPVC resin and Epichlorohydrin (ECH) are on schedule, expected to boost volumes and sales in FY27 and FY28.
- New product evaluations and projects on existing and newly acquired land at Dahej aim to add growth beyond 2028, focusing on import substitution chemicals with expected double-digit CAGR (~12-13%) over 10 years.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
- A 19.8 MW wind-solar hybrid power plant expansion is underway, expected to add to a total of 38 MW hybrid capacity.
- Ongoing expansion capex for FY '26 is around INR 450 crores, with roughly INR 120 crores already spent; a similar capex range (~INR 400-450 crores) is expected for FY '27.
- Company is evaluating a project within the existing complex to optimize infrastructure; this will be the last at this site.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Chlorotoluene plant is currently in trial stage, with commercial orders expected to start from Q4 FY '26; exact revenue from this is not yet specified but clarity expected by Q4.
- Pipeline customers for chlorine include Meghmani company and other nearby companies supplied via pipeline; chlorine is partly sold through pipeline and partly to the general market.
- No specific details provided about a disclosed orderbook or pending orders for other products in this transcript.
2 more points management made on order book & pipeline
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Frequently Asked Questions
What were Epigral Ltd Q1 FY26 results?
Epigral aims for consistent growth driven by expansion and diversification into multiproducts serving various industries. Epigral targets consistent growth driven by expansion and diversification into multiproduct segments catering to various industries.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 17.8 with a market cap of ₹4,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is currently executing capex projects including doubling the capacity of CPVC resin and Epichlorohydrin plants.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.